EP2300 compounds: Focusing on the antiatherosclerotic properties of squalene synthase inhibitors

Current Pharmaceutical Design

Volumn 15, Issue 27, 2009, Pages 3167-3178

  Tavridou, A ^a   Manolopoulos, V G ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Antioxidant; Atherosclerosis; Cholesterol fed rabbit; EP2302; EP2306; Hepatocytes; Squalene synthase inhibitors

Indexed keywords

2 (4 BIPHENYL) 2 (3 NITROOXYPROPOXY) 4 METHYLMORPHOLINE HYDROBROMIDE; 2 (4 BIPHENYL) 4 METHYL OCTAHYDRO 1,4 BENZOXAZIN 2 OL HYDROBROMIDE; 4,1 BENZOXAZEPINE 3 ACETIC ACID DERIVATIVE; ACETIC ACID DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; BMS 188494; BMS188494; EP 2302; EP 2306; ER 27856; ER 28448; EZETIMIBE; GERANYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; QUINUCLIDINE DERIVATIVE; SIMVASTATIN; SQUALENE SYNTHASE INHIBITOR; SQUALESTATIN; SULFANILIC ACID DERIVATIVE; TAK 475; UNCLASSIFIED DRUG; YM 53601; ZARAGOZIC ACID C;

ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; ENZYME SYNTHESIS; HUMAN; HYPERCHOLESTEROLEMIA; IC 50; LIVER TOXICITY; MORTALITY; MUSCLE DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; STRUCTURE ANALYSIS; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIOXIDANTS; ATHEROSCLEROSIS; BIPHENYL COMPOUNDS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; MOLECULAR STRUCTURE; MORPHOLINES; RABBITS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70449373230     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209789057968     Document Type: Review

References (88)

1. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874
2. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126
3. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81: 7B-12B.
4. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278
5. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-1622 (Pubitemid 28248586)
6. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15.
7. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr., Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239 (Pubitemid 38924592)
8. Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Almeras N, et al. Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000; 102: 179-184 (Pubitemid 30451774)
9. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009
10. Smith SC, Jr., Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006; 113: 2363-2372
11. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 1955; 54: 558-559
12. Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol 2008; 101: 20B-6B.
13. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992; 33: 1569-1582
14. Zambon A, Gervois P, Pauletto P, Fruchart JC, Staels B. Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence. Arterioscler Thromb Vasc Biol 2006; 26: 977-986 (Pubitemid 43732101)
15. van Heek M, Farley C, Compton DS, Hoos L, Davis HR. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol 2001; 134: 409-417 (Pubitemid 32989139)
16. Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007; 23: 2009-2026
17. Libby P. The Forgotten Majority: Unfinished Business in Cardiovascular Risk Reduction. J Am Coll Cardiol 2005; 46: 1225-1228 (Pubitemid 41615541)
18. Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007; 11: 1-160, iii-iv. (Pubitemid 47224473)
19. Miettinen TA, Gylling H. Ineffective decrease of serum cholesterol by simvastatin in a subgroup of hypercholesterolemic coronary patients. Atherosclerosis 2002; 164: 147-152 (Pubitemid 34773441)
20. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997; 80: 106-107
21. Bolego C, Baetta R, Bellosta S, Corsini A, Paoletti R. Safety considerations for statins. Curr Opin Lipidol 2002; 13: 637-644
22. Kornbrust DJ, MacDonald JS, Peter CP, Duchai DM, Stubbs RJ, Germershausen JI, et al. Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits. J Pharmacol Exp Ther 1989; 248: 498-505.
23. Masters BA, Palmoski MJ, Flint OP, Gregg RE, Wang-Iverson D, Durham SK. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol 1995; 131: 163-174
24. Okazaki H, Tazoe F, Okazaki S, Isoo N, Tsukamoto K, Sekiya M, et al. Increased cholesterol biosynthesis and hypercholesterolemia in mice overexpressing squalene synthase in the liver. J Lipid Res 2006; 47: 1950-1958 (Pubitemid 44401982)
25. Charlton-Menys V, Durrington PN. Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential. Drugs 2007; 67: 11-16 (Pubitemid 46105084)
26. Flint OP, Masters BA, Gregg RE, Durham SK. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol 1997; 145: 91-98
27. Biller SA, Forster C, Gordon EM, Harrity T, Rich LC, Marretta J, et al. Isoprenyl phosphinylformates: new inhibitors of squalene synthetase. J Med Chem 1991; 34: 1912-1914
28. Biller SA, Forster C, Gordon EM, Harrity T, Scott WA, Ciosek CP, Jr. Isoprenoid (phosphinylmethyl)phosphonates as inhibitors of squalene synthetase. J Med Chem 1988; 31: 1869-1871.
29. Baxter A, Fitzgerald BJ, Hutson JL, McCarthy AD, Motteram JM, Ross BC, et al. Squalestatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo. J Biol Chem 1992; 267: 11705-11708
30. Bergstrom JD, Kurtz MM, Rew DJ, Amend AM, Karkas JD, Bostedor RG, et al. Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc Natl Acad Sci USA 1993; 90: 80-84 (Pubitemid 23010253)
31. Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, et al. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 1992; 33: 1657-1663
32. Magnin DR, Biller SA, Chen Y, Dickson JK, Jr., Fryszman OM, Lawrence RM, et al. alpha-Phosphonosulfonic acids: potent and selective inhibitors of squalene synthase. J Med Chem 1996; 39: 657-660 (Pubitemid 26069686)
33. Ciosek CP, Jr., Magnin DR, Harrity TW, Logan JV, Dickson JK, Jr., Gordon EM, et al. Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo. J Biol Chem 1993; 268: 24832-24837 (Pubitemid 23335498)
34. Lan SJ, Hsieh DC, Hillyer JW, Fancher RM, Rinehart KJ, Warrack BM, et al. Metabolism of alpha-phosphonosulfonate squalene synthase inhibitors. I. Disposition of a farnesylethyl alpha-phosphonosulfonate and ester prodrugs in rats. Drug Metab Dispos 1998; 26: 993-1000.
35. Hiyoshi H, Yanagimachi M, Ito M, Ohtsuka I, Yoshida I, Saeki T, et al. Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3-methylglutaryl-coa reductase inhibitors. J Lipid Res 2000; 41: 1136-1144 (Pubitemid 30483019)
36. Hiyoshi H, Yanagimachi M, Ito M, Saeki T, Yoshida I, Okada T, et al. Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism. Eur J Pharmacol 2001; 431: 345-352 (Pubitemid 33145413)
37. Hiyoshi H, Yanagimachi M, Ito M, Yasuda N, Okada T, Ikuta H, et al. Squalene synthase inhibitors suppress triglyceride biosynthesis through the farnesol pathway in rat hepatocytes. J Lipid Res 2003; 44: 128-135 (Pubitemid 36114778)
38. Dickson JK, Jr., Biller SA, Magnin DR, Petrillo EW, Jr., Hillyer JW, Hsieh DC, et al. Orally active squalene synthase inhibitors: bis((acyloxy)alkyl) prodrugs of the alpha-phosphonosulfonic acid moiety. J Med Chem 1996; 39: 661-664
39. Sharma A, Slugg PH, Hammett JL, Jusko WJ. Estimation of oral bioavailability of a long half-life drug in healthy subjects. Pharm Res 1998; 15: 1782-1786 (Pubitemid 28524592)
40. Brown GR, Clarke DS, Foubister AJ, Freeman S, Harrison PJ, Johnson MC, et al. Synthesis and activity of a novel series of 3-biarylquinuclidine squalene synthase inhibitors. J Med Chem 1996; 39: 2971-2979 (Pubitemid 26251035)
41. McTaggart F, Brown GR, Davidson RG, Freeman S, Holdgate GA, Mallion KB, et al. Inhibition of squalene synthase of rat liver by novel 3′ substituted quinuclidines. Biochem Pharmacol 1996; 51: 1477-1487 (Pubitemid 126333978)
42. Ward WH, Holdgate GA, Freeman S, McTaggart F, Girdwood PA, Davidson RG, et al. Inhibition of squalene synthase in vitro by 3-(biphenyl-4-yl)- quinuclidine. Biochem Pharmacol 1996; 51: 1489-1501
43. Ugawa T, Kakuta H, Moritani H, Matsuda K, Ishihara T, Yamaguchi M, et al. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Br J Pharmacol 2000; 131: 63-70. (Pubitemid 30703185)
44. Ugawa T, Kakuta H, Moritani H, Inagaki O, Shikama H. YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents. Br J Pharmacol 2003; 139: 140-146 (Pubitemid 36645317)
45. Ugawa T, Kakuta H, Moritani H, Shikama H. Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model. Br J Pharmacol 2002; 135: 1572-1578 (Pubitemid 34270930)
46. Miki T, Kori M, Mabuchi H, Tozawa R, Nishimoto T, Sugiyama Y, et al. Synthesis of novel 4,1-benzoxazepine derivatives as squalene synthase inhibitors and their inhibition of cholesterol synthesis. J Med Chem 2002; 45: 4571-4580
47. Nishimoto T, Amano Y, Tozawa R, Ishikawa E, Imura Y, Yukimasa H, et al. Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro. Br J Pharmacol 2003; 139: 911-918 (Pubitemid 36877390)
48. Amano Y, Nishimoto T, Tozawa R, Ishikawa E, Imura Y, Sugiyama Y. Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia. Eur J Pharmacol 2003; 466: 155-161 (Pubitemid 36385101)
49. Shiomi M, Yamada S, Amano Y, Nishimoto T, Ito T. Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/lipid-rich coronary plaques of hypercholesterolaemic rabbits into fibrous lesions. Br J Pharmacol 2008; 154: 949-957 (Pubitemid 351915051)
50. Nishimoto T, Tozawa R, Amano Y, Wada T, Imura Y, Sugiyama Y. Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes. Biochem Pharmacol 2003; 66: 2133-2139
51. Nishimoto T, Ishikawa E, Anayama H, Hamajyo H, Nagai H, Hirakata M, et al. Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs. Toxicol Appl Pharmacol 2007; 223: 39-45. (Pubitemid 47211267)
52. Burnett JR. Drug evaluation: TAK-475 -an oral inhibitor of squalene synthase for hyperlipidemia. Curr Opin Investig Drugs 2006; 7: 850-856 (Pubitemid 44382792)
53. Davidson MH. Squalene synthase inhibition: A novel target for the management of dyslipidemia. Curr Atheroscler Rep 2007; 9: 78-80.
54. Chrysselis MC, Rekka EA, Kourounakis PN. Hypocholesterolemic and hypolipidemic activity of some novel morpholine derivatives with antioxidant activity. J Med Chem 2000; 43: 609-612 (Pubitemid 30127156)
55. Chrysselis MC, Rekka EA, Siskou IC, Kourounakis PN. Nitric oxide releasing morpholine derivatives as hypolipidemic and antioxidant agents. J Med Chem 2002; 45: 5406-5409
56. Tavridou A, Kaklamanis L, Megaritis G, Kourounakis AP, Papalois A, Roukounas D, et al. Pharmacological characterization of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis. Eur J Pharmacol 2006; 535: 34-42.
57. Tavridou A, Kaklamanis L, Papalois A, Kourounakis AP, Rekka E, Kourounakis PN, et al. EP2306, a novel squalene synthase inhibitor, reduces atherosclerosis in the cholesterol-fed rabbit. J Pharmacol Exp Ther 2007; 323: 794-804.
58. Tavridou A, Kaklamanis L, Papalois A, Kourounakis AP, Rekka EA, Kourounakis PN, et al. Antiatherosclerotic properties of EP2302, a novel squalene synthase inhibitor, in the cholesterol-fed rabbit. J Cardiovasc Pharmacol 2008; 51: 573-580
59. Sugano M, Makino N, Yanaga T. The effects of renin-angiotensin system inhibition on aortic cholesterol content in cholesterol-fed rabbits. Atherosclerosis 1996; 127: 123-129 (Pubitemid 26425849)
60. Yang BC, Phillips MI, Mohuczy D, Meng H, Shen L, Mehta P, et al. Increased angiotensin II type 1 receptor expression in hypercholesterolemic atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 1998; 18: 1433-1439 (Pubitemid 28421881)
61. Alfon J, Guasch JF, Berrozpe M, Badimon L. Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors. Atherosclerosis 1999; 145: 325-331
62. Hernandez-Presa MA, Ortego M, Tunon J, Martin-Ventura JL, Mas S, Blanco-Colio LM, et al. Simvastatin reduces NF-kappaB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. Cardiovasc Res 2003; 57: 168-177 (Pubitemid 36009448)
63. Pazzucconi F, Dorigotti F, Gianfranceschi G, Campagnoli G, Sirtori M, Franceschini G, et al. Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity. Atherosclerosis 1995; 117: 189-198
64. Rosenson RS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 2004; 173: 1-12.
65. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005; 96: 24F-33F.
66. Libby P, Aikawa M. Mechanisms of plaque stabilization with statins. Am J Cardiol 2003; 91: 4B-8B.
67. Sumi D, Hayashi T, Thakur NK, Jayachandran M, Asai Y, Kano H, et al. A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects - the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis 2001; 155: 347-357 (Pubitemid 32209305)
68. Mitani H, Egashira K, Ohashi N, Yoshikawa M, Niwa S, Nonomura K, et al. Preservation of endothelial function by the HMG-CoA reductase inhibitor fluvastatin through its lipid-lowering independent antioxidant properties in atherosclerotic rabbits. Pharmacology 2003; 68: 121-130 (Pubitemid 36649404)
69. Rikitake Y, Kawashima S, Takeshita S, Yamashita T, Azumi H, Yasuhara M, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001; 154: 87-96. (Pubitemid 32008567)
70. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-924 (Pubitemid 19101597)
71. Tavridou A, Manolopoulos VG. Antioxidant properties of two novel 2-biphenylmorpholine compounds (EP2306 and EP2302) in vitro and in vivo. Eur J Pharmacol 2004; 505: 213-221 (Pubitemid 39535694)
72. Abuja PM, Lohner K, Prassl R. Modification of the lipid-protein interaction in human low-density lipoprotein destabilizes ApoB-100 and decreases oxidizability. Biochemistry 1999; 38: 3401-3408 (Pubitemid 129501402)
73. Bjorkhem I, Henriksson-Freyschuss A, Breuer O, Diczfalusy U, Berglund L, Henriksson P. The antioxidant butylated hydroxy-toluene protects against atherosclerosis. Arterioscler Thromb 1991; 11: 15-22.
74. Wilson RB, Middleton CC, Sun GY. Vitamin E, antioxidants and lipid peroxidation in experimental atherosclerosis of rabbits. J Nutr 1978; 108: 1858-1867 (Pubitemid 9204021)
75. Witztum JL, Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc Med 2001; 11: 93-102.
76. Ardans JA, Economou AP, Martinson JM, Jr., Zhou M, Wahl LM. Oxidized low-density and high-density lipoproteins regulate the production of matrix metalloproteinase-1 and -9 by activated monocytes. J Leukoc Biol 2002; 71: 1012-1018
77. Liao L, Starzyk RM, Granger DN. Molecular determinants of oxidized low-density lipoprotein-induced leukocyte adhesion and microvascular dysfunction. Arterioscler Thromb Vasc Biol 1997; 17: 437-444 (Pubitemid 27133132)
78. Raij L. Nitric oxide in the pathogenesis of cardiac disease. J Clin Hypertens (Greenwich) 2006; 8: 30-39
79. Goss SP, Kalyanaraman B, Hogg N. Antioxidant effects of nitric oxide and nitric oxide donor compounds on low-density lipoprotein oxidation. Methods Enzymol 1999; 301: 444-453
80. Kurowska EM, Carroll KK. Hypocholesterolemic properties of nitric oxide. In vivo and in vitro studies using nitric oxide donors. Biochim Biophys Acta 1998; 1392: 41-50.
81. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-1135 (Pubitemid 28152885)
82. Laufs U. Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol 2003; 58: 719-731 (Pubitemid 36399228)
83. Tavridou A, Megaritis G, Kourounakis AP, Charalambous A, Manolopoulos VG. EP2306 and EP2302, two novel squalene synthase inhibitors, stimulate eNOS expression in cultured endothelial cells. Endothelium 2007; 14: 239-243 (Pubitemid 47543010)
84. Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther 2001; 299: 818-824
85. Davidson MH. Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Curr Atheroscler Rep 2009; 11: 67-70.
86. Ansquer JC, Foucher C, Aubonnet P, Le Malicot K. Fibrates and microvascular complications in diabetes - insight from the FIELD study. Curr Pharm Des 2009; 15(5): 537-552
87. Hyogo H, Yamagishi S. Advanced glycation end products (AGEs) and their involvement in liver disease. Curr Pharm Des 2008; 14(10): 969-972 (Pubitemid 351753284)
88. Yamagishi S, Matsui T, Nakamura K. Atheroprotective properties of pigment epithelium-derived factor (PEDF) in cardiometabolic disorders. Curr Pharm Des 2009; 15(9): 1027-1033